Changes in Subcellular Distribution and Phosphorylation of GluR1 in Lesioned Striatum of 6-hydroxydopamine-lesioned and L-dopa-treated Rats
Overview
Affiliations
Recent evidence has linked striatal amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor function to the adverse effects of long-term dopaminergic treatment in Parkinson's disease. The phosphorylation of AMPA subunit, GluR1, reflects AMPA receptor activity. To determine whether serine phosphorylation of GluR1 subunit by activation of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) contributes to the process, we examined the effects of unilateral nigrostriatal depletion with 6-hydroxydopamine and subsequent L: -dopa treatment on motor responses and phosphorylation states. Three weeks of L: -dopa administration to rats shortened the duration of the rotational response. We found a significant reduction in the abundance of both phosphorylated GluR1 at serine-831 site (pGluR1S831) and GluR1 in the cell plasma membrane of lesioned striatum. Chronic treatment of lesioned rats with L: -dopa markedly upregulated the phosphorylation of GluR1 in lesioned striatum with a concomitant normalization of the plasma membrane GluR1 abundance, which lasted at least 1 day after withdrawal of chronic L: -dopa treatment. Our immunostaining data showed that these changes were confined to parvalbumin-positive neurons where GluR1 subunits are exclusively expressed. Both the altered motor response duration and the degree of pGluR1S831 were attenuated by the intrastriatal administration of CaMKII inhibitor KN-93. These findings suggest that activation of CaMKII contributes to both development and maintenance of motor response duration alterations, through a mechanism that involves an increase in pGluR1S831 within parvalbumin-positive neurons.
Zhang F, Liu M, Tuo J, Zhang L, Zhang J, Yu C Front Immunol. 2023; 14:1253273.
PMID: 37860013 PMC: 10582719. DOI: 10.3389/fimmu.2023.1253273.
The function of Golgi apparatus in LRRK2-associated Parkinson's disease.
Wei Y, Awan M, Bai L, Bai J Front Mol Neurosci. 2023; 16:1097633.
PMID: 36896008 PMC: 9989030. DOI: 10.3389/fnmol.2023.1097633.
Angelopoulou E, Paudel Y, Julian T, Shaikh M, Piperi C Mol Neurobiol. 2020; 58(4):1372-1391.
PMID: 33175322 DOI: 10.1007/s12035-020-02201-z.
Immunomodulatory drugs alleviate l-dopa-induced dyskinesia in a rat model of Parkinson's disease.
Boi L, Pisanu A, Greig N, Scerba M, Tweedie D, Mulas G Mov Disord. 2019; 34(12):1818-1830.
PMID: 31335998 PMC: 11719776. DOI: 10.1002/mds.27799.
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.
Del Bello F, Giannella M, Giorgioni G, Piergentili A, Quaglia W Biomolecules. 2019; 9(4).
PMID: 30970612 PMC: 6523988. DOI: 10.3390/biom9040142.